Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00068250 · BASELINE

Baseline characteristics

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma · Source last updated 2018-02-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      6
    2. group Id
      BG001
      value
      6
    3. group Id
      BG002
      value
      47
    4. group Id
      BG003
      value
      59
    units
    Participants
groups
  1. description
    Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
    id
    BG000
    title
    Phase I: Temozolomide 100 mg
  2. description
    Rituximab, methotrexate, temozolomide 150 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
    id
    BG001
    title
    Phase I: Temozolomide 150 mg
  3. description
    Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
    id
    BG002
    title
    Phase II: Temozolomide 100 mg
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          43
          upper Limit
          70
          value
          57
        2. group Id
          BG001
          lower Limit
          47
          upper Limit
          72
          value
          62
        3. group Id
          BG002
          lower Limit
          24
          upper Limit
          73
          value
          57
        4. group Id
          BG003
          lower Limit
          24
          upper Limit
          73
          value
          57
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
        2. group Id
          BG001
          value
          2
        3. group Id
          BG002
          value
          24
        4. group Id
          BG003
          value
          30
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          4
        3. group Id
          BG002
          value
          23
        4. group Id
          BG003
          value
          29
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible patients who started study treatment
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      6
    2. group Id
      BG001
      value
      6
    3. group Id
      BG002
      value
      47
    4. group Id
      BG003
      value
      59
    units
    Participants
groups
  1. description
    Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
    id
    BG000
    title
    Phase I: Temozolomide 100 mg
  2. description
    Rituximab, methotrexate, temozolomide 150 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
    id
    BG001
    title
    Phase I: Temozolomide 150 mg
  3. description
    Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
    id
    BG002
    title
    Phase II: Temozolomide 100 mg
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          43
          upper Limit
          70
          value
          57
        2. group Id
          BG001
          lower Limit
          47
          upper Limit
          72
          value
          62
        3. group Id
          BG002
          lower Limit
          24
          upper Limit
          73
          value
          57
        4. group Id
          BG003
          lower Limit
          24
          upper Limit
          73
          value
          57
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
        2. group Id
          BG001
          value
          2
        3. group Id
          BG002
          value
          24
        4. group Id
          BG003
          value
          30
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          4
        3. group Id
          BG002
          value
          23
        4. group Id
          BG003
          value
          29
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible patients who started study treatment

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice